Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BristolMyersSquibb--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab.

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024.

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024

Occidental Petroleum

Visa

Investors continue to look for the market to broaden before jumping in. They may be waiting awhile.

3 Warren Buffett Stocks to Buy Now: June 2024

Shares of Bristol-Myers Squibb Co (NYSE:BMY) have had a tumultuous journey since reaching its all-time high above $80 in December 2022. The stock has plummeted by over 50% and now trades in the low $40s, reflecting a period of significant challenges and investor skepticism.

Bristol-Myers Squibb stock price forecast: Is the downtrend finally over?

Amgen

Ionis Pharma

SPDR S&P Biotech ETF

Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.

M&A Is Back. 4 Stocks That Could Be Targets.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors.

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

Pfizer

High-yield dividend stocks can be potent long-term value creators. Pharma titans Pfizer and Bristol Myers Squibb sport two of the highest yields within their peer group.

Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb

bluebird bio

Gilead Sciences

Neurocrine Biosciences

Novartis

Ultragenyx Pharmaceutical

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline

Dominion Energy

Kenvue

Altria

Rio Tinto plc Sponsored

24/7 Insights Quality dividend stocks can generate solid total returns and yield passive income.

6 of Wall Street's Favorite High-Yield Blue Chip Dividend Stocks to Buy in June

CVS Health

Pfizer stock has been beaten down so far that it offers a dividend yield above 6% at recent prices. Bristol Myers Squibb has been trading for the low multiple of about 7 times trailing free cash flow.

3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade

The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro

AllianceBernstein Hld

Kinder Morgan

MPLX

Whirlpool

The artificial intelligence rally over the past year and a half, led by the so-called Magnificent 7 stocks, has been remarkable if you owned those stocks.

Goldman Sachs Has 6 High-Yield Dividend Stocks to Buy in June

Chevron

The latest readings on inflation show some cooling, and stocks seem to like it. However, it's important to be clear about why investors feel bullish.

3 High-Yield Dividend Stocks for Income Now and Growth Later

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Augtyro--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive.

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb Company stock has taken a big tumble in the past quarter following its sharply reduced earnings guidance, but there are still plenty of positives going for it. Better than expected revenue growth in Q1 2024, earnings reduction being restricted to one year only and its recent cost reduction initiatives indicate better times from 2025 onwards. Its still elevated forward P/E indicates it's unlikely to see an uptick anytime this year, but it's still a good time to start buying the stock for next year.

Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least

SL Green Realty

The markets had a strong week, with the S&P 500 gaining 0.97% and the Dow Jones Industrial Average gaining 1.6%. Yields on the 10-year Treasury shot up to 4.9% ahead of the FOMC meeting. The Dividend Harvesting Portfolio traded sideways but continues to generate consistent dividend income and exceed invested capital.

Dividend Harvesting Portfolio Week 171: $17,100 Allocated, $1,524.12 In Projected Dividends

Evotec SE

Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / June 12, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a research payment of US$ 20 m to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.

Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb

Bristol Myers Squibb (BMY) reachead $43.02 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.

Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know

Celgene

Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 11:20 AM ET Company Participants Chris Boerner - Board Chair and Chief Executive Officer Conference Call Participants Chris Shibutani - Goldman Sachs Good morning, still, I think, everybody, and welcome. We are very pleased that you're joining us here on the Second Day of the Goldman Sachs Healthcare Conference.

Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference

Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.8% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources.

Why Bristol Myers Squibb Is A Top Socially Responsible Dividend Stock

Celanese

General Motors

KeyCorp

Paramount Global

Sirius XM Holdings Inc

The Oracle of Omaha is by far the most well-known long-term investor we have alive today, and if you are a newbie, looking into Warren Buffett stocks to sell is a good way to weed out the bad stocks from your portfolio. I believe Berkshire Hathaway (NYSE: BRK-A , NYSE: BRK-B ) alone makes for a pretty good starter portfolio, as it acts like an exchange-traded fund with solid growth.

7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too)

Bristol Myers Squibb has solid fundamentals that have been clouded by the rise of interest rates. The company's revenue is at risk due to higher debt burdens and future patent expiry concerns, but recent acquisitions and cost-saving measures provide potential for growth. BMY stock is undervalued compared to its sector, with a potential upside of 29% and a fair value estimate of $48 per share.

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Central Garden & Pet Company

Clean Energy Fuels

DigitalBridge Group

Five9

Revolution Medicines

Uranium Energy

For many investors, especially those who are just building a portfolio, undervalued stocks under $50 hold significant appeal. Investors can start a significant position, in terms of shares owned, for a small investment.

The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024

Blackstone Secured Lending Fund

Realty Income Corp

Vici Properties

The Dividend Harvesting Portfolio generated over $100 of dividend income in May, with a return on invested capital of 14.14%. The portfolio's diversification helped stabilize market conditions, with a 1.45% growth in profitability despite market declines. Dividend income from various investment baskets, including equities, ETFs, REITs, CEFs, BDCs, and treasuries, contributes to portfolio growth.

Dividend Harvesting Portfolio Week 170: $17,000 Allocated, $1,515.47 In Projected Dividends

I-Mab

I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. Collaboration builds on promising safety and efficacy data from the givastomig monotherapy study reported at the European Society of Medical Oncology Congress 2023.

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

News for Bristol-Myers Stock (BMY)